Optimization of vonoprazan‐amoxicillin dual therapy for eradicating <i>Helicobacter pylori</i>infection in China: A prospective, randomized clinical pilot study

Abstract

Neither 7- or 10-day VA dual therapy with b.i.d. or t.i.d. amoxicillin provides satisfied efficacy as the first-line treatment for H. pyloriinfection in China. Further optimization is needed.